AI bosses’ safety push sparks rift inside OpenAI and Anthropic
Staff at the Silicon Valley companies are grappling with how to turn AI slowdown rhetoric into reality
Staff at the Silicon Valley companies are grappling with how to turn AI slowdown rhetoric into reality Grouped from 6 articles across 3 sources.
Ranked reports inside the event cluster. Open any publisher link to read the original coverage.
Staff at the Silicon Valley companies are grappling with how to turn AI slowdown rhetoric into reality
Discussions have been ongoing since Google's Demis Hassabis released a proposal in July calling for a U.S.-led "Standards Body," the spokesperson said.
Comments from the two tech leaders landed days after Anthropic's Dario Amodei published an essay urging the AI industry to slow the pace of model development.
They are exploring a self-regulatory body modelled on US financial regulator that oversees brokers and investment firms.
Anthropic CEO has called for government regulation and slower AI development to assess safety risks.
Policymakers and others in the industry question if government regulation is needed to keep AI under human control.
Nearby clusters pulled from title, summary, and keyword similarity in PostgreSQL.
Anthropic and OpenAI are proposing embedded AI evaluators to help manage risk of models causing catastrophic harm to society, but the idea has some issues.
OpenAI CEO Sam Altman said that the world was right in fearing some companies developing AI getting too much power during a Salesforce's Dreamforce conference on Tuesday in San Francisco. Grouped from 2 articles across 2 sources.
Heads of top US AI labs including OpenAI have called for a slowdown in the pace of advanced AI development.
Two opposing camps are emerging in the AI regulation debate, with Trump and Huang on one side and Amodei. Altman and Musk on the other.
Anthropic’s CEO says he ‘didn’t appreciate’ the speed with which AI’s growth would underpin the global economy.
The deal underscores a broader push by drugmakers to integrate AI across research and development to boost new drug discovery.